Sehn LH, Salles G (2021) Diffuse large B-cell lymphoma. N Engl J Med 384(9):842–858

Article  PubMed  PubMed Central  Google Scholar 

Crump M, Neelapu SS, Farooq U et al (2017) Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study. Blood 130(16):1800–1808

Article  PubMed  PubMed Central  Google Scholar 

Suzuki T, Maruyama D, Miyagi-Maeshima A et al (2021) Clinicopathological analysis of primary refractory diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone chemoimmunotherapy. Cancer Med 10(15):5101–5109

Article  PubMed  PubMed Central  Google Scholar 

Mounier N, Canals C, Gisselbrecht C et al (2012) High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry. Biol Blood Marrow Transplant 18(5):788–793

Article  PubMed  Google Scholar 

Nowakowski GS, Blum KA, Kahl BS et al (2016) Beyond RCHOP: a blueprint for diffuse large B cell lymphoma research. J Natl Cancer Inst 108(12):257

Article  Google Scholar 

Makita S, Yoshimura K, Tobinai K (2017) Clinical development of anti-CD19 chimeric antigen receptor T-cell therapy for B-cell non-Hodgkin lymphoma. Cancer Sci 108(6):1109–1118

Article  PubMed  PubMed Central  Google Scholar 

Neelapu SS, Locke FL, Bartlett NL et al (2017) Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med 377(26):2531–2544

Article  PubMed  PubMed Central  Google Scholar 

Locke FL, Ghobadi A, Jacobson CA et al (2019) Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1-2 trial. Lancet Oncol 20(1):31–42

Article  PubMed  Google Scholar 

Kato K, Fujii N, Makita S et al (2023) A phase 2 study of axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma in Japan: 1-year follow-up and biomarker analysis. Int J Hematol 117(3):409–420

Article  PubMed  Google Scholar 

Schuster SJ, Bishop MR, Tam CS et al (2019) Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med 380(1):45–56

Article  PubMed  Google Scholar 

Goto H, Makita S, Kato K et al (2020) Efficacy and safety of tisagenlecleucel in Japanese adult patients with relapsed/refractory diffuse large B-cell lymphoma. Int J Clin Oncol 25(9):1736–1743

Article  PubMed  PubMed Central  Google Scholar 

Abramson JS, Palomba ML, Gordon LI et al (2020) Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study. Lancet 396(10254):839–852

Article  PubMed  Google Scholar 

Makita S, Yamamoto G, Maruyama D et al (2022) Phase 2 results of lisocabtagene maraleucel in Japanese patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma. Cancer Med 11(24):4889–4899

Article  PubMed  PubMed Central  Google Scholar 

Kamdar M, Solomon SR, Arnason J et al (2022) Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial. Lancet 399(10343):2294–2308

Article  PubMed  Google Scholar 

Abramson JS, Solomon SR, Arnason J et al (2023) Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study. Blood 141(14):1675–1684

Article  PubMed  Google Scholar 

Sehgal A, Hoda D, Riedell PA et al (2022) Lisocabtagene maraleucel as second-line therapy in adults with relapsed or refractory large B-cell lymphoma who were not intended for haematopoietic stem cell transplantation (PILOT): an open-label, phase 2 study. Lancet Oncol 23(8):1066–1077

Article  PubMed  Google Scholar 

Sehgal A, Hoda D, Riedell PA, et al. Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study. Blood Adv. 2025 in press.

Alaggio R, Amador C, Anagnostopoulos I et al (2022) The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 36(7):1720–1748

Article  PubMed  PubMed Central  Google Scholar 

Lee DW, Santomasso BD, Locke FL et al (2019) ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells. Biol Blood Marrow Transplant 25(4):625–638

Article  PubMed  Google Scholar 

Jain T, Bar M, Kansagra AJ et al (2019) Use of chimeric antigen receptor T cell therapy in clinical practice for relapsed/refractory aggressive B cell non-Hodgkin lymphoma: an expert panel opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant 25(12):2305–2321

Article  PubMed  Google Scholar 

Bachanova V, Bishop MR, Dahi P et al (2020) Chimeric antigen receptor T cell therapy during the COVID-19 pandemic. Biol Blood Marrow Transplant 26(7):1239–1246

Article  PubMed  PubMed Central  Google Scholar 

Cheson BD, Fisher RI, Barrington SF et al (2014) Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J Clin Oncol 32(27):3059–3068

Article  PubMed  PubMed Central  Google Scholar 

Meignan M, Sasanelli M, Casasnovas RO et al (2014) Metabolic tumour volumes measured at staging in lymphoma: methodological evaluation on phantom experiments and patients. Eur J Nucl Med Mol Imaging 41(6):1113–1122

Article  PubMed  Google Scholar 

Riedell PA, Grady CB, Nastoupil LJ et al (2025) Lisocabtagene maraleucel for relapsed/refractory large B-cell lymphoma: a cell therapy consortium real-world analysis. Blood Adv 9(5):1232–1241

Article  PubMed  Google Scholar 

Chiappella A, Casadei B, Chiusolo P et al (2024) Axicabtagene ciloleucel treatment is more effective in primary mediastinal large B-cell lymphomas than in diffuse large B-cell lymphomas: the Italian CART-SIE study. Leukemia 38(5):1107–1114

Article  PubMed  PubMed Central  Google Scholar 

Galtier J, Mesguich C, Sesques P et al (2025) <article-title update="added">Outcomes of patients with relapsed or refractory primary mediastinal B‐cell lymphoma treated with anti‐CD19 CAR‐T cells: carthym, a study from the French national DESCAR‐T registry. Hemasphere 9(2):e70091

Article  PubMed  PubMed Central  Google Scholar 

Samples L, Sadrzadeh H, Frigault MJ et al (2025) Outcomes among adult recipients of CAR T-cell therapy for Burkitt lymphoma. Blood 145(23):2762–2767

Article  PubMed  Google Scholar 

De Philippis C, Mannina D, Giordano L et al (2023) Impact of preemptive use of tocilizumab on chimeric antigen receptor T cell outcomes in non-Hodgkin lymphoma. Transplant Cell Ther 29(7):429.e1-429.e6

Article  PubMed  Google Scholar